Navigation Links
Cellectis to Present at the FASEB Summer Research Conference on Genome Engineering
Date:6/2/2010

PARIS, June 2 /PRNewswire-FirstCall/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, announces today that Frederic Paques, PhD, Chief Scientific Officer, Julianne Smith, PhD, head of the Meganuclease Recombination System group at Cellectis genome surgery, and Feng Zhang, PhD, Research Director at Cellectis plant sciences have been invited to present Cellectis' results on meganucleases and genome surgery at the FASEB Summer Research Conference on Genome Engineering to be held in Steamboat Springs, Colorado, USA, on June 6-11, 2010.  

Targeted approaches have emerged today as an alternative to current random insertion strategies for gene therapy. Meganucleases, the most specific endonucleases, represent ideal tools for targeted genome editing, or genome surgery. They can induce up to 20% of gene insertion into chosen human genes.

Dr Paques will discuss "Engineering Meganucleases for Genome Engineering Purposes" on June 7, 2010, at 7:00AM, during an oral session on Engineering Customized Nucleases, while Dr Smith will present "Meganucleases for Genome Surgery" on June 8, 2010, at 8:45AM, during an oral session on Nuclease-Enhanced Genome Engineering in Mammalian Cells. Dr Zhang will talk about "Modification of Plant Genomes using Engineered Meganucleases" on June 8, 2010, at 10:00AM, during an oral session on Nuclease-Enhanced Genome Engineering in Model Organisms and Plants.

About Cellectis

Cellectis is a pioneer in the field of genome engineering. The company designs and markets finnovative tools -meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.

To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.

Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code : ALCLS) in Paris and has secured over EUR 70 million in funding since inception.

More information at www.cellectis.com

Follow us on Twitter: twitter.com/cellectis

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.


'/>"/>
SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology
2. Cellectis and Regeneron Sign an Agreement Over the use of Homologous Recombination Technology
3. Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology
4. Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting
5. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
6. Avicena Group to Present at Noble Financial Conference
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CEL-SCI to Present at the Noble Financial Conference
11. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
Breaking Biology Technology:
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
Breaking Biology News(10 mins):